'Finally there's some hope.' 9News
Eli Lilly and Co is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai.
Scientists say while these drugs may mark a new era in Alzheimer's therapy, huge questions remain about which patients should try them and how much benefit they'll really notice. The study had a few twists. Patients were switched to dummy infusions if enough amyloid cleared out — something that happened to about half within a year.
How much difference does that make? It means donanemab slowed patients' worsening by about four to seven months, the JAMA report concluded.Among the donanemab recipients with lower tau levels, 47 per cent were considered stable a year into the study compared with 29 per cent of those who got the dummy version.
Scientists already know that patients getting any amyloid-targeted therapy need repeat brain scans to check for those side effects — a costly and time-consuming hurdle.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Teen threatened with knife in Sydney store robberyA young woman has been threatened with a knife during a robbery in western Sydney. 9News
Read more »
Lawyers review footage after Lehrmann broadcast on SevenThe footage is being reviewed by lawyers defending a defamation claim from former political staffer Bruce Lehrmann. 9News
Read more »
Lawyers review footage after Lehrmann broadcast on SevenHiggins alleged Lehrmann raped her inside the parliament house office of then coalition defence industry minister Linda Reynolds, their boss, in 2019. 9News
Read more »
Trial begins over toddler's death in neighbour's unitCecil Kennedy has pleaded not guilty to the toddler's manslaughter. 9News
Read more »
The global office property crisis has finally hit AustraliaThe decision to limit redemptions from an unlisted Charter Hall office property fund shows investors are spooked, and the market is in a difficult spot.
Read more »
Bullock’s promotion explains the world’s new inflation problemThe desire by a central bank to avoid costly outcomes from policy action or inaction is a rational one, it also gives rise to a specific form of bias that shapes monetary policy in both good times and bad.
Read more »